Uridine triacetate

Drug Profile

Uridine triacetate

Alternative Names: PN 401; TAU; Triacetyluridine; Vistogard; Vistonuridine; Xuriden

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wellstat Therapeutics Corporation
  • Class Antidepressants; Chemoprotectants; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Adenosine triphosphatase stimulants; Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Orotic aciduria; Poisoning; Mitochondrial disorders
  • New Molecular Entity No

Highest Development Phases

  • Marketed Orotic aciduria; Poisoning
  • Phase III Pancreatic cancer
  • Phase II Gastric cancer
  • No development reported Neurodegenerative disorders
  • Discontinued Diabetic neuropathies

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Neurodegenerative-disorders in USA (PO)
  • 08 Sep 2016 Wellstat Therapeutics completes a phase III trial in Orotic-aciduria (In infants, In children, In adolescents, In adults) in USA (NCT02110147)
  • 23 Aug 2016 Launched for Orotic-aciduria in USA (PO) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top